Zevra Therapeutics, Inc.
ZVRA
$9.98
-$0.21-2.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 183.36% | 605.36% | 481.73% | 495.65% | -6.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 183.36% | 605.36% | 481.73% | 495.65% | -6.79% |
| Cost of Revenue | 11.27% | -46.24% | 246.46% | 668.57% | 11.33% |
| Gross Profit | 205.38% | 1,683.41% | 1,441.32% | 486.34% | -8.69% |
| SG&A Expenses | 26.42% | 4.49% | 64.88% | 96.81% | 4.82% |
| Depreciation & Amortization | -80.45% | -79.61% | 4.53% | 5.69% | 109.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.65% | -29.29% | 35.29% | 7.75% | -2.20% |
| Operating Income | 160.42% | 115.17% | 48.19% | 73.83% | -1.71% |
| Income Before Tax | 162.19% | 97.06% | 487.34% | 88.52% | -2.39% |
| Income Tax Expenses | -96.74% | -- | 3,041.43% | 1,788.57% | -- |
| Earnings from Continuing Operations | 134.04% | 98.36% | 474.94% | 81.36% | -79.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 134.04% | 98.36% | 474.94% | 81.36% | -79.67% |
| EBIT | 160.42% | 115.17% | 48.19% | 73.83% | -1.71% |
| EBITDA | 170.29% | 117.65% | 51.97% | 80.38% | 4.19% |
| EPS Basic | 131.39% | 98.60% | 366.41% | 85.60% | -30.09% |
| Normalized Basic EPS | 159.05% | 97.18% | 51.05% | 91.14% | 26.75% |
| EPS Diluted | 129.14% | 98.56% | 357.17% | 85.60% | -30.09% |
| Normalized Diluted EPS | 156.73% | 97.18% | 52.40% | 91.14% | 26.75% |
| Average Basic Shares Outstanding | 5.47% | 17.03% | 30.74% | 29.48% | 38.11% |
| Average Diluted Shares Outstanding | 9.78% | 17.03% | 34.43% | 29.48% | 38.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |